-
公开(公告)号：US20140155584A1
公开(公告)日：2014-06-05
申请号：US13977207
申请日：2011-12-30
Applicant: Kathleen Ann Elias , Gregory Landes , Shweta Singh , Wouter Korver , Andrew Walling Drake , Mary Haak-Frendscho , Gyorgy Pal Snell , Vinay Bhaskar
Inventor： Kathleen Ann Elias , Gregory Landes , Shweta Singh , Wouter Korver , Andrew Walling Drake , Mary Haak-Frendscho , Gyorgy Pal Snell , Vinay Bhaskar
IPC: C07K16/28
CPC classification number: C07K16/40 , A61K47/6871 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N9/99
Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
Abstract translation: 公开了结合人CD38和食蟹猴CD38的分离的抗体。 还公开了包含所公开的抗体的药物组合物，以及使用所公开的抗体的治疗和诊断方法。
-
公开(公告)号：US20100285037A1
公开(公告)日：2010-11-11
申请号：US12738546
申请日：2008-10-03
Applicant: Arie Abo , Wouter Korver
Inventor： Arie Abo , Wouter Korver
IPC: A61K39/395 , C07K16/28 , C07K16/46 , C07H21/04 , C12N5/07 , G01N33/566 , A61P35/02 , A61P35/00
CPC classification number: C07K16/2851 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/734 , C07K2317/77 , C07K2317/92 , C07K2319/21
Abstract: Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.
Abstract translation: 描述了抗CLL-1抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合CLL-1并治疗以CLL-1表达为特征的疾病如血液恶性肿瘤的方法。
-
13.发明申请Reducing the risk of human anti-human antibodies through V gene manipulation 审中-公开通过V基因操作降低人抗人抗体的风险公开(公告)号：US20050260679A1
公开(公告)日：2005-11-24
申请号：US11084554
申请日：2005-03-17
Applicant: Sirid-Aimee Kellerman , Larry Green , Wouter Korver
Inventor： Sirid-Aimee Kellerman , Larry Green , Wouter Korver
CPC classification number: C07K16/00 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/56
Abstract: The present embodiments relate to methods of identifying and creating human, or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included.
Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述抗体或人源化抗体在施用于人宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。
-
公开(公告)号：US08993726B2
公开(公告)日：2015-03-31
申请号：US13488031
申请日：2012-06-04
Applicant: Arie Abo , Wouter Korver
Inventor： Arie Abo , Wouter Korver
IPC: C12P21/08 , C07K16/28 , G01N33/574 , A61K39/00
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92 , G01N33/57426
Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.
Abstract translation: 描述了抗NTB-A抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合NTB-A并治疗以NIB-A表达为特征的血液恶性肿瘤的疾病的方法。
-
公开(公告)号：US20130273077A1
公开(公告)日：2013-10-17
申请号：US13488031
申请日：2012-06-04
Applicant: Arie Abo , Wouter Korver
Inventor： Arie Abo , Wouter Korver
IPC: C07K16/28
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92 , G01N33/57426
Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.
Abstract translation: 描述了抗NTB-A抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合NTB-A并治疗以NIB-A表达为特征的血液恶性肿瘤的疾病的方法。
-
Patent Agency Ranking
公开(公告)号：US08193320B2
公开(公告)日：2012-06-05
申请号：US12962227
申请日：2010-12-07
Applicant: Arie Abo , Wouter Korver
Inventor： Arie Abo , Wouter Korver
IPC: C07K16/00
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K2299/00 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/92 , G01N33/57426
Abstract: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
Abstract translation: 描述了抗NTB-A抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这样的抗体和抗原结合区域结合NTB-A并治疗以NTB-A表达为特征的疾病如血液恶性肿瘤的方法。
-
公开(公告)号：US20100291108A1
公开(公告)日：2010-11-18
申请号：US12738539
申请日：2008-10-01
Applicant: Arie Abo , Wouter Korver
Inventor： Arie Abo , Wouter Korver
IPC: A61K39/395 , C07K16/28 , C07H21/04 , C12N5/10 , G01N33/566 , A61P35/00 , A61P35/02
CPC classification number: C07K16/3061 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
Abstract: Anti-IREM-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind IREM-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of IREM-1.
Abstract translation: 描述了抗-IREM-1抗体及其抗原结合片段，以及包含这种抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合IREM-1并治疗以IREM-1表达为特征的血液恶性肿瘤的疾病的方法。
-
18.发明申请公开(公告)号：US20100028906A1
公开(公告)日：2010-02-04
申请号：US12577696
申请日：2009-10-12
Applicant: Sirid-Aimee Kellermann , Larry L. Green , Wouter Korver
Inventor： Sirid-Aimee Kellermann , Larry L. Green , Wouter Korver
IPC: G01N33/53 , A01K67/027
CPC classification number: G01N33/6854 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/56 , G01N33/5088
Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。
-
公开(公告)号：US07625549B2
公开(公告)日：2009-12-01
申请号：US11136250
申请日：2005-05-23
Applicant: Sirid-Aimée Kellermann , Larry L. Green , Wouter Korver
Inventor： Sirid-Aimée Kellermann , Larry L. Green , Wouter Korver
IPC: A61K49/00 , A01K67/027 , A01K67/00
CPC classification number: G01N33/6854 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/56 , G01N33/5088
Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。
-
20.发明申请公开(公告)号：US20060021074A1
公开(公告)日：2006-01-26
申请号：US11136250
申请日：2005-05-23
Applicant: Sirid Kellermann , Larry Green , Wouter Korver
Inventor： Sirid Kellermann , Larry Green , Wouter Korver
IPC: A01K67/027
CPC classification number: G01N33/6854 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/56 , G01N33/5088
Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
Abstract translation: 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.042 seconds)
